Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis

Xiyue Li, Richa Goswami, Shumin Yang, Qifu Li, Xiyue Li, Richa Goswami, Shumin Yang, Qifu Li

Abstract

Objective: The accuracy of aldosterone/direct renin concentration ratio (ADRR) as a screening test in patients with primary aldosteronism (PA) varies widely across the studies. Therefore, we conducted a meta-analysis to assess the accuracy of ADRR.

Methods: A literature search was performed in PubMed, Embase, and the Cochrane library published between April 1971-February 2016. Studies focusing on the accuracy of ADRR for PA screening were included. Two authors independently extracted information regarding patient characteristics, antihypertensives status, true positives, true negatives, false positives, and false negatives. The random-effects model was used for statistical analysis. Heterogeneity was explored by subgroup analysis and meta-regression.

Results: Nine studies involving 974 patients were included. The overall sensitivity, specificity, area under the curve, and diagnostic odds ratio of ADRR were 0.89 (95% confidence interval (CI) 0.84-0.93), 0.96 (95% CI 0.95-0.98), 0.985 and 324 respectively, with substantial heterogeneity. Meta-regression showed that antihypertensive status affects the ADRR and may account for the heterogeneity (p=0.03). Subgroup analysis of patients who discontinued the antihypertensives revealed a sensitivity of 0.99 (95% CI, 0.95-1.00) and a specificity of 0.98 (95% CI, 0.96-0.99).

Conclusions: This study demonstrates the efficacy of ADRR as a screening test for PA. However, as antihypertensive drugs can interfere with the interpretation of ADRR, it is recommended to interrupt therapy or at least replace with analogues that do not significantly affect the ADRR value.

Keywords: Primary aldosteronism; aldosterone-to-renin ratio; aldosterone/direct renin concentration; direct renin concentration; screening test.

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

© The Author(s) 2016.

Figures

Figure 1.
Figure 1.
Literature search results for identification, exclusion and selection of studies. DRC: direct renin concentration; PA: primary aldosteronism.
Figure 2.
Figure 2.
Sensitivity and specificity of studies: (a) forest plot of sensitivities and specificities of nine studies; (b) summary receiving operation characteristic curve (SROC) curve for individual studies on the accuracy of diagram primary aldosteronism (PA). AUC: area under the curve; CI: confidence interval; SE: standard error.
Figure 3.
Figure 3.
Funnel plots of publication bias in nine included studies. ESS: effective sample size.
Figure 4.
Figure 4.
(a) Forest plot of sensitivities and specificities of the five studies with discontinuation of antihypertensives. (b) Forest plot of sensitivities and specificities of the four studies without discontinuation of antihypertensives. (c) Forest plot of sensitivities and specificities of the six studies that set essential hypertension (EH) patients as control group. CI: confidence interval.

References

    1. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3–17.
    1. Kaplan NM. Primary aldosteronism: An update on screening, diagnosis and treatment. J Hypertens 2008; 26: 1708–1709.
    1. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–1248.
    1. Gruson D, Maisin D, Lison P, et al. Two-site automated chemiluminescent assay for measurement of immunoreactive renin. Biomarkers 2011; 16: 605–609.
    1. Morganti A and European study group for the validation of DiaSorin LDRA. A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin. J Hypertens 2010; 28: 1307–1312.
    1. Dorrian CA, Toole BJ, Alvarez-Madrazo S, et al. A screening procedure for primary aldosteronism based on the Diasorin Liaison automated chemiluminescent immunoassay for direct renin. Ann Clin Biochem 2010; 47: 195–199.
    1. Balas M, Zosin I, Maser-Gluth C, et al. Indicators of mineralocorticoid excess in the evaluation of primary aldosteronism. Hypertens Res 2010; 33: 850–856.
    1. Corbin F, Douville P, Lebel M. Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism. Int J Nephrol Renovasc Dis 2011; 4: 115–120.
    1. Diederich S, Mai K, Bahr V, et al. The simultaneous measurement of plasma-aldosterone- and -renin-concentration allows rapid classification of all disorders of the renin-aldosterone system. Exp Clin Endocrinol Diabetes 2007; 115: 433–438.
    1. Lonati C, Bassani N, Gritti A, et al. Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension. J Hypertens 2014; 32: 627–634.
    1. Perschel FH, Schemer R, Seiler L, et al. Rapid screening test for primary hyperaldosteronism: Ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50: 1650–1655.
    1. Tzanela M, Effraimidis G, Vassiliadi D, et al. The aldosterone to renin ratio in the evaluation of patients with incidentally detected adrenal masses. Endocrine 2007; 32: 136–142.
    1. Willenberg HS, Kolentini C, Quinkler M, et al. The serum sodium to urinary sodium to (serum potassium)2 to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism. Eur J Clin Invest 2009; 39: 43–50.
    1. Jansen PM, van den Born BJ, Frenkel WJ, et al. Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism. J Hypertens 2014; 32: 115–126.
    1. Fischer E, Beuschlein F, Bidlingmaier M, et al. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 2011; 12: 43–48.
    1. Glinicki P, Jeske W, Bednarek-Papierska L, et al. The ratios of aldosterone / plasma renin activity (ARR) versus aldosterone/direct renin concentration (ADRR). J Renin Angiotensin Aldosterone Syst 2015; 16: 1298–1305.
    1. Rossi GP, Barisa M, Belfiore A, et al. The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010; 28: 1892–1899.
    1. Trenkel S, Seifarth C, Schobel H, et al. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002; 110: 80–85.
    1. Unger N, Lopez Schmidt I, Pitt C, et al. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. Eur J Endocrinol 2004; 150: 517–523.
    1. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 10: 25.
    1. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882–893.
    1. Tanabe A, Naruse M, Takagi S, et al. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88: 2489–2494.
    1. Yin G, Zhang S, Yan L, et al. One-hour upright posture is an ideal position for serum aldosterone concentration and plasma renin activity measuring on primary aldosteronism screening. Exp Clin Endocrinol Diabetes 2012; 120: 388–394.
    1. Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699–705.
    1. Seifarth C, Trenkel S, Schobel H, et al. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57: 457–465.
    1. Ahmed AH, Gordon RD, Taylor P, et al. Effect of atenolol on aldosterone/renin ratio calculated by both plasma Renin activity and direct Renin concentration in healthy male volunteers. J Clin Endocrinol Metab 2010; 95: 3201–3206.
    1. Stowasser M, Ahmed AH, Pimenta E, et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170–176.
    1. Niizuma S, Nakahama H, Kamide K, et al. The cutoff value of aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine. Clin Exp Hypertens 2008; 30: 640–647.
    1. Barigou M, Ah-Kang F, Orloff E, et al. Effect of postural changes on aldosterone to plasma renin ratio in patients with suspected secondary hypertension. Ann Cardiol Angeiol (Paris) 2015; 64: 169–174.
    1. Wu VC, Kuo CC, Chang HW, et al. Diagnosis of primary aldosteronism: Comparison of post-captopril active renin concentration and plasma renin activity. Clin Chim Acta 2010; 411: 657–663.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner